triple negative breast cancer

[Journal of the American Chemical Society] The authors described the synthesis of multiple bromodomain-containing protein 4 (BRD4)– casein kinase 2dual inhibitors based on rational drug design, structure–activity relationship, and in vitro and in vivo evaluations, and 44e was identified to possess potent and balanced activities against BRD4.

[Military Medical Research] Researchers evaluated the antitumor activities of LR004-VC-MMAE against epidermal growth factor receptor (EGFR)-positive TNBC and further studied its possible mechanism of antitumor action.

[Cell Death & Disease] Scientists found that repression of the oncogenic transcription factor FOXM1 using FOXM1 shRNA or FOXM1 inhibitor FDI-6 could sensitize BRCA-proficient TNBC to PARP inhibitor Olaparib in vitro and in vivo.

[Molecular Cancer Research] Scientists observed that expression of a construct derived from the N-terminus of Stx4, which interfered with Stx4-Munc18c interaction, led to perturbed trafficking of MT1-MMP, and reduced invadopodium-based invasion in vitro, in models of TNBC.

[Scientific Reports] Researchers developed a protocol for processing human adipose derived MSC secretome formulation of varying concentration. Its molecular composition was evaluated, and its effectiveness in vitro using breast cancer cell lines.

[G1 Therapeutics, Inc.] G1 Therapeutics, Inc. announced that the company has initiated a Phase II, single arm, open-label study of trilaciclib in patients with early-stage triple negative breast cancer designed to further investigate the role of trilaciclib in modulating the anti-tumor immune response.